| 000 | 01125 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250516114829.0 | ||
| 264 | 0 | _c20130207 | |
| 008 | 201302s 0 0 eng d | ||
| 022 | _a1095-6859 | ||
| 024 | 7 |
_a10.1016/j.ygyno.2012.09.011 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSalani, Ritu | |
| 245 | 0 | 0 |
_aHere it comes....the role of cost-effective analysis. _h[electronic resource] |
| 260 |
_bGynecologic oncology _cNov 2012 |
||
| 300 |
_a265-6 p. _bdigital |
||
| 500 | _aPublication Type: Editorial; Comment | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aChemoradiotherapy _xeconomics |
| 650 | 0 | 4 |
_aCisplatin _xtherapeutic use |
| 650 | 0 | 4 |
_aDeoxycytidine _xanalogs & derivatives |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aUterine Cervical Neoplasms _xtherapy |
| 650 | 0 | 4 | _aGemcitabine |
| 700 | 1 | _aO'Malley, David M | |
| 773 | 0 |
_tGynecologic oncology _gvol. 127 _gno. 2 _gp. 265-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ygyno.2012.09.011 _zAvailable from publisher's website |
| 999 |
_c22181410 _d22181410 |
||